Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria

Abstract A single 300 mg dose of tafenoquine (an 8-aminoquinoline), in combination with a standard 3-day course of chloroquine, is approved in several countries for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged ≥ 16 years. Despite this, questions have arisen o...

Full description

Bibliographic Details

Published in:	Malaria Journal
Main Authors:	Raman Sharma, Hema Sharma, Siôn Jones, Isabelle Borghini-Fuhrer, Gonzalo J. Domingo, Rachel A. Gibson, Katie Rolfe, Lionel Tan, Ioana Gabriela Fiţa, Chao Chen, Panayota Bird, Anup Pingle, Stephan Duparc
Format:	Article
Language:	English
Published:	BMC 2024-05-01
Subjects:	Plasmodium vivax malaria Radical cure Tafenoquine Benefit–risk
Online Access:	https://doi.org/10.1186/s12936-024-04924-z